ClinicalTrials.gg
RecruitingNCT06589544INCEPTUpdated Sep 19, 2024

Non-pharmacological Care for Depression in Cancer Patients Using VR and TMS

An interventional study of Virtual Reality-based Cognitive Remediation (VR-COG) + Treatment as Usual (TAU) and Repetitive transcranial magnetic stimulation (rTMS) + Treatment as usual (TAU) in Depressive Symptoms, Quality of Life and Cognitive Impairment, sponsored by University Hospital of Ferrara. Recruiting at 2 sites in Italy. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by University Hospital of Ferrara · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 103 studies in Depression with a site in Italy — 33 open to participants now, 34 under way, 2 of them phase 3. Depression · Italy.

Planned enrollment
39th of 75
100 · median 104
Started
2024
with 6 others
No phase
48 of 103
21 open now
Primary completion
2026-12
later than 20 of 33 live
Registered
80th of 103
by date

Among the 103 studies in Depression with a site in Italy, this one is the 39th largest by planned enrollment of the 75 interventional ones that give a count, is one of 7 that started in 2024, is one of 48 with no phase, reaches primary completion later than 20 of the 33 other live ones, and was the 80th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

33 of the 103 studies in Depression with a site in Italy are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Depression with a site in Italy, or all of them as a file.
02

Study summary

Despite its significant impact on individuals and healthcare systems, substantial gaps remain in the clinical and rehabilitative management of depression in oncology patients.

Depression in cancer patients is often under-recognized and untreated, and screening tools and structured healthcare pathways are lacking. Even when depression is identified in oncology patients, evidence of effective treatments is limited. There are no specific guidelines for psychotropic drug use in cancer patients, and antidepressant efficacy is uncertain despite their frequent use.

Emerging strategies like transcranial magnetic stimulation and cognitive rehabilitation show promising findings. However, the cost-effectiveness of therapeutic strategies is understudied.

Repetitive transcranial magnetic stimulation (rTMS) is already used for the treatment and relapse prevention of depression both as monotherapy and as an add-on to antidepressant pharmacotherapy, and it appears effective in improving cognitive performance. However, it has not yet been applied to treat depressive disorders in oncology patients.

Virtual reality-based cognitive behavioral intervention (VR-COG) is designed to improve cognitive functioning, a central feature of depression in oncological conditions. VR-COG enhances learning and skill acquisition with better ecological efficiency than traditional cognitive remediation programs. VR approaches are well-received by oncology patients and show promise in reducing anxiety and depressive symptoms.

The trial aims to evaluate the effectiveness of highly specialized, nonpharmacological interventions on depressive symptoms and quality of life in oncology patients. Specifically, repetitive Transcranial Magnetic Stimulation (rTMS) and Virtual Reality-based Cognitive Remediation (VR-COG) will be analyzed, alongside standard Treatment as Usual (TAU), in comparison to TAU alone. This trial also aims at evaluate cognitive functioning, depression-related conditions and the cost-effectiveness of the interventions under study.

03

Conditions studied

  • Depressive Symptoms
  • Quality of Life
  • Cognitive Impairment

Keywords

  • Depression
  • Cognitive functions
  • Quality of Life
  • Cancer
  • Virtual reality
  • Repetitive Transcranial Magnetic Stimulation
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of oncological disease in the last 5 years
  • Diagnosis of Major Depressive Disorder, without psychotic symptoms, according to criteria
  • 17-item Hamilton Rating Scale for Depression (HAM-D-17) (score ≥14)
  • Age: 18 years or older
  • Oncological disease in a non-advanced stage ( Performance Status > 80)

Exclusion criteria

Exclusion Criteria:

  • Current or prior hospitalization in the next 6 months
  • Planned surgery in the next 6 months
  • Suicidal ideation
  • Substance use
  • History of significant head trauma, neurological disorders, intellectual deficits
  • Recurrent seizures resulting from head trauma or conditions lowering seizure threshold
  • Concurrent use of medications that increase the risk of epileptic seizures (e.g., antipsychotics, tricyclics, theophylline)
  • Glaucoma, retinal detachment, or other serious vision impairments that may prevent the use of virtual reality technology
  • Severe problems with autonomous ambulation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Virtual Reality-based Cognitive Remediation (VR-COG)

    Virtual Reality-based Cognitive Remediation (VR-COG) + Treatment as usual (TAU) The "VSail 3D" experimental protocol includes scenarios (virtual environments) dedicated to the sport of sailing. It is based on the software CEREBRUM-VELA (Idego-Promind, srl, Rome, Italy). Frequency: 24 sessions, 2 times a week, for 12 consecutive weeks. The duration of each session is 50 minutes.

    Device: Virtual Reality-based Cognitive Remediation (VR-COG) + Treatment as Usual (TAU)

  • Experimental
    Repetitive transcranial magnetic stimulation (rTMS)

    Repetitive transcranial magnetic stimulation (rTMS) + Treatment as usual (TAU) rTMS group will receive active rTMS using the MagVenture MagPro X100 System (MagVenture A/S, Denmark) equipped with a MagVenture Cool-B65 A/P double-faced coil and a neuronavigation system (Localite GmbH, Sankt Augustin, Germany). Frequency: 24 sessions, 2 times a week, for 12 consecutive weeks. The duration of each session is 60 minutes.

    Device: Repetitive transcranial magnetic stimulation (rTMS) + Treatment as usual (TAU)

  • Active comparator
    Treatment as Usual (TAU)

    Treatment as Usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https://www.aiom.it), includes an initial psychiatric visit and eventual pharmacological therapy with psychiatric follow-up plus psychological counseling. Frequency: 12 weeks. Each counseling session lasts 45-50 minutes, and will be conducted on a monthly basis.

    Other: Treatment as Usual (TAU)

Interventions

  • DeviceVirtual Reality-based Cognitive Remediation (VR-COG) + Treatment as Usual (TAU)

    The "CEREBRUM-VELA" virtual reality software is made up of exercises designed to train different cognitive functions (i.e.: executive functions, motor ability, language). The different degrees of difficulty are designed to adapt to the user's functional diagnosis. Each session, after an initial part of welcome, psychoeducation and orientation to the instrument, involves alternating virtual reality exercises, positive and corrective feedback and suggestions of practical homework that the individual should try to do during his day. Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions).

  • DeviceRepetitive transcranial magnetic stimulation (rTMS) + Treatment as usual (TAU)

    Active rTMS stimulation will be delivered at 90% of the resting Motor Threshold (rMT), adjusted for the depth of the fcMRI-identified target. Personalized targets created for each individual will be located at various cortical depths. For safety reasons, the stimulation intensity will never exceed 120% of the rTMS. Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions).

  • OtherTreatment as Usual (TAU)

    Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions).

06

What researchers measure

Primary outcomes

  1. Hamilton Depression rating scale (HAM-D 17)

    The Ham-D is the most widely used clinician-administered depression assessment scale.The original version contains 17 items pertaining to symptoms of depression experienced over the past week.

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1)

  2. Dropout rates; Proportion of recruited participants among those considered eligible

    Feasibility will be assessed based on tolerability (dropout rates) and acceptability (proportion of recruited participants among those considered eligible).

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1)

  3. Simulator Sickness Questionnaire (SSQ)

    Feasibility will be assessed based on side effects through Simulator Sickness Questionnaire (SSQ) self-report questionnaire that evaluates the frequency of unwanted effects due to virtual reality technologies, such as nausea, dizziness, headaches, eye strain, etc. 16 items.

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention)

  4. TMSens_Q

    It was developed to report secondary effects following rTMS application. The use of the structured rTMS questionnaire will help to monitor the safety of rTMS.

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention)

Secondary outcomes

  1. EuroQol (EQ)-5D

    It is self-report questionnaire to assess quality of life and heath status according to five dimensions.

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1)

  2. SF-12

    It is a self-report questionnaire to assess quality of life considering two dimensions, about physical health and mental health.

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1)

  3. Demoralization Scale (DS)

    It is a 24-item self-administered questionnaire with four subscales: discouragement, loss of meaning/purpose, dysphoria, sense of failure.

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1)

  4. Post-Traumatic Embitterment Disorder Self-Rating Scale

    It is a rating scale to assess embitterment reactions to negative life events

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1)

  5. Brief Symptom Inventory (BSI)

    Il is a questionnaire to evaluate symptoms of psychological distress

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1)

  6. Insomnia Severity Index (ISI)

    It is a tool to assess the severity of daytime and nighttime components of insomnia.

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1)

  7. Biological Rhythms Interview for Assessment in Neuropsychiatry (BRIAN)

    It is a scale consisting of 18 items to assess four areas of circadian rhythm difficulties: sleep, activity, social rhythms, and eating patterns.

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1)

  8. Activities of Daily Living (ADL)

    It is an instrument to assess disability levels.

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1)

  9. Psychosocial Adjustment to Illness (PAIS)

    I is a self-report instrument to assess seven dimensions about disability and quality of life.

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1)

  10. Toronto Alexithymia Scale 20-item (TAS-20)

    It is a self-report questionnaire to assess alexithymia.

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1)

  11. Screen for Cognitive Impairment in Psychiatry (SCIP)

    It is an instrument to assess cognitive deficit according to five subscales: immediate memory, working memory, phonemic verbal fluency, delayed memory, and psychomotor speed.

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1)

  12. Trail Making Test

    Preliminary measures of effectiveness on executive function

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1)

  13. Digit Span

    Preliminary measures of effectiveness on memory

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1)

  14. Stroop Test

    Preliminary measures of effectiveness on executive function

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1)

  15. Frontal Assessment Battery (FAB)

    Preliminary measures of effectiveness on executive function

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1)

  16. Rey's Word Test

    Preliminary measures of effectiveness on memory

    Time frame: T0 (0 months - baseline); T1 (3 months - post intervention); T2 (3 months after T1); T3 (6 months after T1)

  17. Matrix test

    Preliminary measure of effectiveness on selective attention.

    Time frame: T0 (0 months-baseline), T1 (3 months - post intervention), T2 (3 months after T1), T3 (6 months after T1)

Other outcomes

  1. Cost-effectiveness

    The cost effectiveness will be computed as the ratio of total costs divided by the mean improvements of quality of life across interventions (TAU, TAU+rTMS, TAU+VRCOG). Total costs will include the costs of the healthcare consultations (visits in the TAU condition), psychotropic drugs, equipment and staff. Total costs will be computed as the sum of these costs of each intervention, divided by the number of patients. Quality of life improvements will be computed as the difference between baseline (T0) vs endpoint (T3) quality of life.

    Time frame: T0 (0 months - baseline); T3 (6 months after T1-post intervention)

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 28 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2024
First posted
Sep 19, 2024
StartActual
Aug 21, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06589544
Collaborators
University Hospital of Cagliari
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Aug 21, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 19, 2024

Study contacts

Martino Belvederi Murri, MD
Contact
martino.belvederimurri@unife.it
00393335248720
Barbara Zaccagnino, PsyD
Contact
barbara.zaccagnino@edu.unife.it
00393288657355
Luigi Grassi, MD, PhD
principal investigator · Università degli Studi di Ferrara

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion